Intellia Therapeutics, Inc. (NTLA)
| Previous Close | 21.53 |
| Open | 21.56 |
| Bid | 21.30 x 200 |
| Ask | 21.42 x 400 |
| Day's Range | 21.22 - 21.73 |
| 52 Week Range | 20.78 - 47.48 |
| Volume | |
| Avg. Volume | 1,549,935 |
| Market Cap | 2.054B |
| Beta (5Y Monthly) | 1.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.42 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 70.96 |
Simply Wall St.Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65%
Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of...
ZacksIntellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
GlobeNewswireIntellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of NTLA-2001. NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to inactivate the TTR gene and thereby prevent the production of TTR protein for the treatment
